Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know

Why Understanding Endpoints Matters for Investors

When a biotech company announces Phase 3 top-line results, the stock can move 30-100%+ in minutes. The difference between a "great" result and a "disappointing" result often comes down to a few key statistical measures that many investors struggle to interpret.

Understanding primary endpoints, p-values, hazard ratios, and confidence intervals is not just academic — it's the difference between making informed decisions and gambling on headlines.

Primary vs. Secondary Endpoints

Primary Endpoint

The primary endpoint is the main outcome measure that the trial is statistically powered to detect. It is defined before the trial begins and is what the FDA primarily evaluates when making approval decisions.

Common primary endpoints in biotech:

• Overall Survival (OS): The gold standard — does the drug help patients live longer? Measured as the time from randomization to death from any cause.
• Progression-Free Survival (PFS): Time from randomization to disease progression or death. Commonly used in oncology as a faster-to-measure proxy for OS.
• Objective Response Rate (ORR): The percentage of patients whose tumors shrink by a defined amount. Used for accelerated approval.
• HbA1c reduction: Standard primary endpoint for diabetes drugs.
• Reduction in exacerbation rate: Common in respiratory and autoimmune diseases.

Secondary Endpoints

Additional outcome measures that provide supporting evidence. Important, but the FDA generally requires the primary endpoint to be met before considering secondaries.

Hierarchical Testing

Many trials use a pre-specified testing hierarchy: if the primary endpoint is statistically significant, secondary endpoints are tested in order. If any endpoint in the hierarchy fails, subsequent endpoints cannot be declared significant — even if their p-values look compelling.

Understanding P-Values

What a P-Value Actually Means

The p-value is the probability of observing results at least as extreme as the actual results, assuming the drug has no effect (the null hypothesis). A small p-value means the results are unlikely to have occurred by chance.

• p < 0.05: The standard threshold for statistical significance. The FDA generally requires this level.
• p < 0.01: Strong evidence
• p < 0.001: Very strong evidence
• p = 0.06: Not statistically significant, even though it's close. "Near misses" at p=0.05 are not wins.

Common Misinterpretations

• P-value is NOT the probability that the drug works: A p-value of 0.01 does not mean there's a 99% chance the drug is effective
• Statistical significance ≠ clinical significance: A drug might show a statistically significant but clinically meaningless benefit (e.g., 2-week improvement in survival)
• Multiple comparisons inflate p-values: Testing many endpoints increases the chance of finding a false positive. This is why the FDA requires pre-specified primary endpoints and multiplicity adjustments.

Hazard Ratios (HR)

Hazard ratios are the most important statistic in oncology trials and any trial measuring time-to-event endpoints.

How to Read a Hazard Ratio

The hazard ratio compares the rate of events (death, disease progression) between the treatment and control groups:

• HR < 1.0: Treatment is better than control (lower risk of event)
• HR = 1.0: No difference between treatment and control
• HR > 1.0: Treatment is worse than control

Interpreting the Magnitude

• HR = 0.50: 50% reduction in the rate of events — a very strong result
• HR = 0.70: 30% reduction — a solid, clinically meaningful result in most settings
• HR = 0.80: 20% reduction — may be significant in large trials but raises questions about clinical meaningfulness
• HR = 0.90: 10% reduction — marginal benefit, typically insufficient for approval as a single agent

Confidence Intervals

The hazard ratio is always reported with a 95% confidence interval (CI). The CI tells you the range within which the true effect likely falls:

• CI does not cross 1.0: The result is statistically significant (consistent with p < 0.05)
• CI crosses 1.0: The result is NOT statistically significant
• Narrow CI: More precise estimate (large trial, many events)
• Wide CI: Less precise estimate (small trial, few events)

Example: HR = 0.65 (95% CI: 0.48 - 0.88) — treatment reduces the event rate by 35%, the CI doesn't cross 1.0, so this is statistically significant.

Other Key Statistics

Median Survival Times

Often reported alongside hazard ratios. Example: "Median PFS was 12.3 months with treatment vs. 8.1 months with placebo." The absolute difference (4.2 months) helps assess clinical significance.

Kaplan-Meier Curves

Survival curves plotted over time. Key things to look for:

• Early separation: Curves that separate early suggest a rapid treatment effect
• Sustained separation: Curves that remain separated over time suggest a durable benefit
• Crossing curves: If the curves cross, the treatment may only benefit certain subgroups or time periods
• Tail behavior: A "plateau" in the treatment arm (curve levels off) can suggest some patients are potentially cured

Number Needed to Treat (NNT)

How many patients need to be treated for one additional patient to benefit. Lower is better. NNT of 5-10 is considered good for most serious conditions.

Subgroup Analyses

Companies often present treatment effects broken down by subgroups (age, disease stage, biomarker status). Important caveats:

• Pre-specified subgroups are more reliable than post-hoc analyses
• Small subgroups have wide confidence intervals and are unreliable
• Subgroup effects should be directionally consistent with the overall result
• The FDA generally expects the overall population to show benefit, not just a subgroup

How to Evaluate Top-Line Results

When a biotech company announces Phase 3 results, evaluate them systematically:

1. Did the trial meet its primary endpoint? This is the threshold question. If no, the stock will likely decline regardless of secondary endpoints.
2. What was the magnitude of the effect? A hazard ratio of 0.65 is very different from 0.92, even if both are statistically significant.
3. Was the p-value strong? p < 0.001 provides more confidence than p = 0.048 (barely significant).
4. Was the safety profile acceptable? Even strong efficacy can be undermined by serious adverse events.
5. Were secondary endpoints consistent? Strong primary + strong secondaries = robust data package.
6. How does it compare to competitors? Context matters — a drug with HR 0.75 in a space where competitors show HR 0.60 faces a challenging competitive landscape.

Summary

Clinical trial statistics are the language of biotech investing. Mastering primary endpoints, p-values, hazard ratios, and confidence intervals allows you to make rapid, informed assessments when Phase 3 data is released — often within the critical minutes before the market fully prices in the results.

Track all upcoming Phase 3 readouts and clinical trial milestones with BioSniper's real-time catalyst calendar at biosniper.co/calendar/phase3.